Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway

Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials

(2017) Tomasz Charytoniuk et al.   NUTRITION

Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development

(2017) Kun He et al.   Oncotarget

GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway

(2016) Qin He et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Nonalcoholic Fatty Liver Disease

(2016) Fernando Bril et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice

(2016) Feng Zhou et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

(2016) Matthew J. Armstrong et al.   JOURNAL OF HEPATOLOGY

NAFLD and diabetes mellitus

(2016) Herbert Tilg et al.   Nature Reviews Gastroenterology & Hepatology

Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice

(2016) Takaya Yamamoto   WORLD JOURNAL OF GASTROENTEROLOGY

Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes

(2014) Yan Bi et al.   ACTA DIABETOLOGICA

DPP-4 Inhibitors Repress NLRP3 Inflammasome and Interleukin-1beta via GLP-1 Receptor in Macrophages Through Protein Kinase C Pathway

(2014) Yao Dai et al.   CARDIOVASCULAR DRUGS AND THERAPY

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes

(2014) Ning Shao et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Liraglutide reduces lipid accumulation in steatotic L-02 cells by enhancing autophagy

(2014) SHI-WEI ZHOU et al.   Molecular Medicine Reports

Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin

(2013) Latt S Mansor et al.   Cardiovascular Diabetology

Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo

(2013) K. H. Williams et al.   ENDOCRINE REVIEWS

Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?

(2012) Y. Yilmaz   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKC  Activation in Diabetes

(2012) A. Mima et al.   DIABETES

Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells

(2011) Timea Csak et al.   HEPATOLOGY

Management of type 2 diabetes: new and future developments in treatment

(2011) Abd A Tahrani et al.   LANCET

Immunodeficiency and Genetic Defects of Pattern-Recognition Receptors

(2011) Mihai G. Netea et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

(2010) D. J. Drucker et al.   DIABETES CARE

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

A role for mitochondria in NLRP3 inflammasome activation

(2010) Rongbin Zhou et al.   NATURE

Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome

(2010) Kiichi Nakahira et al.   NATURE IMMUNOLOGY

The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity

(2008) ZhengZheng Li et al.   HEPATOLOGY